Monthly Archives:

Sipuleucel-T Treatment Results in Humoral Spread Associated with Improved Overall Survival

SAN FRANCISCO—Overall survival (OS) was improved in patients with advanced prostate cancer following treatment with Provenge® (sipuleucel-T), according to results of the IMPACT, the pivotal trial of sipuleucel-T. Charles Drake, MD, and colleagues recently utilized data from the IMPACT trial to determine whether sipuleucel-T also elicits humoral antigen spread that may be associated with clinical benefit. They presented results of ... Read More »

One in Five Cancer Trials End Early due to Incomplete Enrollment

SAN FRANCISCO—The clinical trials enterprise is fraught with complications and obstacles to achieving results, particularly in the genitourinary oncology literature. Prostate cancer trials, however, seemed to largely escape the problems of early termination compared to all oncology trials. As part of a research effort to better understand the scope of the problem, Matthew D. Galsky, MD, and colleagues examined the ... Read More »

Obese Patients with Localized Prostate Cancer at Increased Risk of Biochemical Failure and Mortality

SAN FRANCISCO—Among patients with localized prostate cancer (CaP) receiving intensity-modulated radiation therapy (IMRT), those with higher levels of obesity may be at increased risk of biochemical failure (BF) and prostate cancer mortality. That was among the findings of a study conducted by Lora S. Wang, MD, and colleagues. Study results were reported during a poster session at the 2014 Genitourinary ... Read More »

Encouraging Results about Overall Response Rates in Patients Treated with ODM-201

SAN FRANCISCO—In one of several trials evaluating the safety and efficacy of the newer-generation androgen-blocker, ODM-201, at this year’s Genitourinary Cancers Symposium, the vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) were shown to reach stable disease at 12 weeks when treated with the novel agent. ODM-201 is a novel androgen-receptor inhibitor by blocking nuclear translocation; The ARADES ... Read More »

Androgen Receptor Is Important Driver of MDV3100 Resistance

SAN FRANCISCO—There is, according to researchers, controversy surrounding recent reports linking androgen receptor (AR) variants (AR-Vs) to castration-resistant prostate cancer (CRPC), specifically the biologic significance of AR-Vs in AR-regulated cell survival and proliferation, independent of AR full length. To define the functional role of AR-FL and AR-Vs in MDV3100-resistant (MDV-R), Yoshiaki Yamamoto and colleagues designed antisense oligonucleotide (ASO) targeting exon ... Read More »

Robotic Surgery Associated with Improved Positive Margins versus Open Radical Prostatectomy

SAN FRANCISCO—Among men with intermediate and high-risk prostate cancer, robotic-assisted radical prostatectomy (RARP) was associated with improved survival margin status compared with open radical prostatectomy (ORP). That was the finding of a study designed to compare surgical margin status by surgical approach by Jim C. Hu, MD, and colleagues. The researchers presented their findings during a poster session at the ... Read More »

Radiotherapy/Antiandrogen Combination Doubles 10-Year Survival Rate in Patients with Advanced Prostate Cancer

SAN FRANCISCO—The addition of radiotherapy to oral antiandrogen therapy significantly reduced 10- and 15-year cancer-specific mortality rates in men with locally advanced or histologically aggressive prostate cancer, according to updated research presented at the 2014 Genitourinary Cancers Symposium. The results of the extended analysis of the Scandinavian Prostate Cancer Group’s Study VII (SPCG-7) were presented by lead author Sophie D. ... Read More »

Enzalutamide Delays Disease Progression, Improves Survival in Chemo-naïve Patients

SAN FRANCISCO—Updated results from the PREVAIL study show a 30% increase in overall survival with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC), potentially extending patients’ time until last-resort treatment with chemotherapy.  Tomasz M. Beer, MD, from the Knight Cancer Institute at Oregon Health & Science University in Portland, reported the updated results at the 2014 Genitourinary Cancers Symposium. ... Read More »